NCT03911557 2025-11-12
Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors
University of Kentucky
Phase 2 Completed
University of Kentucky
Swiss Cancer Institute
MedImmune LLC
MedImmune LLC
Spanish Lung Cancer Group
National Institutes of Health Clinical Center (CC)
Weill Medical College of Cornell University
Oncovir, Inc.
MedImmune LLC